A Multinational, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study to Assess the Efficacy and Safety of Lu AA21004 in Patients With Major Depressive Disorder.
Phase of Trial: Phase II/III
Latest Information Update: 15 Feb 2017
At a glance
- Drugs Vortioxetine (Primary)
- Indications Major depressive disorder
- Focus Therapeutic Use
- Sponsors Takeda Global Research and Development Center
- 01 Sep 2015 Results of meta analysis of pooled data from 9 trials presented at the 28th Annual Congress of the European College of Neuropsychopharmacology.
- 24 May 2012 Actual end date (1 Apr 2012) added as reported by ClinicalTrials.gov.
- 24 May 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.